此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

NT-i7(Efineptakin alfa),一种长效的人IL-7,Yescarta®(Axicabtagene cileleucel)或后双贝氏菌(Lisocabtagene Maraleucel),具有复发/耐火性大B-Cell淋巴瘤的受试者

2026年9月24日 更新者:Washington University School of Medicine

A Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Diffuse large B-cell lymphoma is the most commonly occurring subtype of non-Hodgkin lymphoma, but treatment is often not curative, with as many as 50% of patients with adverse risk factors developing relapsed/refractory disease. CAR T-cell therapy has revolutionized modern cancer therapy, with axicabtagene ciloleucel and lisocabtagene maraleucel (anti-CD19 CAR T-cell therapies) FDA approved for second- or later-line treatment of relapsed/refractory large B-cell lymphoma.

IL-7 plays a crucial role in T-cell homeostasis by inducing thymic differentiation, peripheral expansion, and extrathymic differentiation. It is the main regulator of T-cell hemostasis, inducing T-cell growth and proliferation in lymphopenic patients. There is data that suggests that exposure of T-cells to IL-7 may expand T-cells, prevent T-cell exhaustion, and improve effector functions.

NT-I7 is a long-acting human IL-7 cytokine which has been shown in nonclinical studies to increase peripheral T-cells, antitumor efficacy, and tumor infiltrating lymphocytes, either as a monotherapy or in combination with chemo/radiotherapy and/or immune checkpoint inhibitors and CAR T therapy.

This study is testing the hypothesis that the administration of NT-I7 following standard of care (SOC) approved CD19 CAR T-cell therapies for subjects with relapsed/refractory large B-cell lymphoma (LBCL) will be safe and tolerable and may increase the expansion and persistence of CAR T-cells in vivo, which may result in increased tumor response rate and improved clinical outcomes.

研究概览

研究类型

介入性

注册 (估计的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Zachary D Crees, M.D.
  • 电话号码:314-273-1039
  • 邮箱:zcrees@wustl.edu

学习地点

    • Missouri
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University School of Medicine
        • 副研究员:
          • John F DiPersio, M.D., Ph.D.
        • 副研究员:
          • Feng Gao, Ph.D.
        • 接触:
        • 首席研究员:
          • Zachary D Crees, M.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically confirmed relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, DLBCL arising from an indolent lymphoma, grade 3B follicular lymphoma and primary mediastinal large B-cell lymphoma.

  • Measurable disease by IWG response criteria for lymphoma.

    • Baseline FDG-PET/CT scan must show FDG-avid lesions compatible with CT-defined anatomical tumor sites.
    • A previously irradiated lesion can be considered a target lesion if it is well defined, measurable, and has clearly progressed following radiation.
    • FDG-PET/CT scans done as SOC up to 60 days pre-lymphodepletion therapy will be allowed. NOTE: After eligibility is confirmed, restaging FDG-PET/CT scans will not be used to change eligibility.
  • Eligible for treatment with an FDA-approved SOC CD19 CAR T-cell therapy respective to the current FDA-approved CAR T-cell label for axi-cel(Yescarta®) or liso-cel (Breyanzi®).

  • If the patient has previously received an autologous stem cell transplant, s/he must be at least 3 months post-transplant.

  • At least 18 years of age.

  • ECOG performance status ≤ 2

  • Adequate bone marrow and organ function at the start of lymphodepleting chemotherapy as pre-conditioning for SOC CD19 CAR T-cell infusion as defined below:

    • Absolute neutrophil count ≥ 1.0 K/cumm
    • Platelets ≥ 50 K/cumm
    • Hemoglobin ≥ 8.0 g/dL
    • Total bilirubin ≤ 1.5 x IULN or direct bilirubin ≤ IULN for patients with total bilirubin levels > 1.5 x IULN (except for patients with Gilbert's syndrome, who must have a baseline total bilirubin ≤ 3.0 mg/dL)
    • AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN (except for patients with documented liver involvement or bone metastases, who must have an AST and/or ALT ≤ 5.0 x IULN)
    • Alkaline phosphatase ≤ 2.5 x IULN (except for patients with liver metastasis, who must have an alkaline phosphatase ≤ 5.0 x IULN)
    • Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault
    • INR and aPTT ≤ 1.5 x IULN unless the patient is receiving anticoagulant therapy and the PT or aPTT is within the therapeutic range for the anticoagulant. Patients who are on anticoagulation should be able to hold the anticoagulant for 4-5 half-lives of the anticoagulant prior to IM NT-I7 injection to reduce risk of hematoma.
  • ECG demonstrating Fridericia's corrected QT interval (QTcF) < 500 ms; patients with QTcF ≥ 500 ms will require clearance by a cardiologist.

  • The effects of NT-I7 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days after the last NT-I7 injection. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.

  • Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

  • Previous receipt of an allogeneic solid organ transplant or bone marrow transplant.

  • Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.

  • Chemotherapy or biologic or hormonal therapy for prior or concurrent cancer treatment, within 14 days prior to the first NT-I7 injection.

    • NOTE: Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable.
  • Currently receiving any other investigational agents, or received within 14 days prior to the first NT-I7 injection.

  • Documented active central nervous system (CNS) involvement by lymphoma.

  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to NT-I7 or other agents used in the study.

  • Presence of clinically significant, unresolved toxicities from prior anticancer therapy, defined as having not received to grade ≤ 1 (with the exception of alopecia and laboratory values listed per the inclusion criteria). Patients with irreversible toxicity that is not reasonably expected to be exacerbated by NT-I7 may be included (e.g., hearing loss, peripheral neuropathy) after consultation with the PI.

  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection (including active hepatitis A or mycobacterium tuberculosis (testing not required))

    • Congestive heart failure with NYHA Class ≥ 2

    • Uncontrolled atrial fibrillation

    • Any of the following within 6 months prior to day of CAR T-cell administration:

      • Unstable angina pectoris
      • Myocardial infarction
      • Coronary artery bypass grafting
      • Coronary angioplasty
      • Coronary stenting
      • Clinically significant cardiac arrhythmia and/or conduction abnormality
    • Other clinically significant cardiac disease that, in the opinion of the treating physician and/or PI, is a contraindication to study treatment

  • History of autoimmune disease for the past 2 years prior to enrollment, including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

    • NOTE: The following are exceptions to this criterion: vitiligo, alopecia, type 1 diabetes mellitus, autoimmune hypothyroidism stable on hormone replacement, psoriasis not severe enough to require systemic treatment, diverticulitis not associated with inflammatory bowel disease.
  • Contraindication to intramuscular therapy.

  • Receipt of a live, attenuated vaccine within 30 days prior to NT-I7 injection.

    • NOTE: Patients, if enrolled, should not receive live vaccines during the study period and through 30 days after the last NT-I7 injection. The administration of inactivated vaccines is permitted at any time per the discretion of the treating physician.
  • Pregnant and/or breastfeeding and/or expecting to conceive or father children within the study duration (from enrollment through 90 days after last dose of NT-I7). Women of childbearing potential (including women who have had a tubal ligation) must have a negative serum or urine pregnancy test within 72 hours prior to CAR-T administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible.

  • Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible.

  • History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
实验性的:Dose Escalation Dose Level 1 Starting Dose: NT-I7

NT-I7 will be administered as an intramuscular injection at 600 μg/kg on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections.

实验性的:Dose Escalation Dose Level 2: NT-I7

NT-I7 will be administered as an intramuscular injection at 720 μg/kg on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections.

实验性的:Dose Expansion (RP2D): NT-I7

NT-I7 will be administered as an intramuscular injection at the recommended phase 2 dose on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of adverse events
大体时间:From start of CAR T-cell infusion (day 0) through day 90 (post CAR T-cell infusion)

Measured per CTCAE v 5.0. CRS and ICANS will be graded per ASTCT guidelines

From start of CAR T-cell infusion (day 0) through day 90 (post CAR T-cell infusion)
Maximum tolerated dose of NT-I7 (Dose Escalation only)
大体时间:From first dose of NT-I7 until 14 days after the second dose NT-I7 dose (estimated to be 35 days)

Determined by incidence and nature of dose-limiting toxicities (DLTs). DLTs are defined in the protocol.

From first dose of NT-I7 until 14 days after the second dose NT-I7 dose (estimated to be 35 days)
Recommended phase 2 dose of NT-I7 (Dose Escalation only)
大体时间:Through 90 days after CAR T-cell infusion

Determined by the potential correlation of dose levels with safety and efficacy parameters.

Through 90 days after CAR T-cell infusion

次要结果测量

结果测量
措施说明
大体时间
通过定量DNA PCR和/或流式细胞术测量的NT-I7对CAR T细胞扩增的影响
大体时间:从第0天至CAR T细胞输注后第42天
从第0天至CAR T细胞输注后第42天
Overall response rate (ORR)
大体时间:Through completion of follow-up (estimated to be 1 year)

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Partial response (PR) rate
大体时间:Through completion of follow-up (estimated to be 1 year)

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Complete response (CR) rate
大体时间:Through completion of follow-up (estimated to be 1 year)

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Duration of response (DoR)
大体时间:Through completion of follow-up (estimated to be 1 year)

For responders only: defined as the time from the first occurrence of a documented objective response (PR or CR) to the time of the first documented disease progression or death from any cause, whichever occurs first, per IWG.

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Progression-free survival (PFS)
大体时间:Through completion of follow-up (estimated to be 1 year)

Defined as the time from the CAR T-cell infusion (Day 0) to the first occurrence of progression or death from any cause, whichever occurs first, per IWG.

Through completion of follow-up (estimated to be 1 year)
Overall survival (OS)
大体时间:Through completion of follow-up (estimated to be 1 year)

Defined as the time from CAR T-cell infusion (Day 0) to death from any cause.

Through completion of follow-up (estimated to be 1 year)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Zachary D Crees, M.D.、Washington University School of Medicine

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月12日

初级完成 (估计的)

2027年11月30日

研究完成 (估计的)

2028年8月31日

研究注册日期

首次提交

2025年6月26日

首先提交符合 QC 标准的

2025年6月26日

首次发布 (实际的)

2025年7月4日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅